{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Combined+Immunodeficiency+Syndrome&page=2",
    "query": {
      "condition": "Severe Combined Immunodeficiency Syndrome",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Combined+Immunodeficiency+Syndrome&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T22:07:07.976Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03513328",
      "title": "Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bone Marrow Failure Syndrome",
        "Thalassemia",
        "Sickle Cell Disease",
        "Diamond Blackfan Anemia",
        "Acquired Neutropenia in Newborn",
        "Acquired Anemia Hemolytic",
        "Acquired Thrombocytopenia",
        "Hemophagocytic Lymphohistiocytoses",
        "Wiskott-Aldrich Syndrome",
        "Chronic Granulomatous Disease",
        "Common Variable Immunodeficiency",
        "X-linked Lymphoproliferative Disease",
        "Severe Combined Immunodeficiency",
        "Hurler Syndrome",
        "Mannosidosis",
        "Adrenoleukodystrophy"
      ],
      "interventions": [
        {
          "name": "Thiotepa--single daily dose",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa--escalated dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "3 Months to 39 Years"
      },
      "enrollment_count": 6,
      "start_date": "2018-06-15",
      "completion_date": "2023-02-19",
      "has_results": true,
      "last_update_posted_date": "2023-09-15",
      "last_synced_at": "2026-07-23T22:07:07.976Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03513328"
    },
    {
      "nct_id": "NCT01019876",
      "title": "Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Bone Marrow Failure",
        "Osteopetrosis",
        "Fanconi Anemia",
        "Severe Combined Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Rabbit Anti-thymocyte Globulin",
          "type": "DRUG"
        },
        {
          "name": "Horse Anti-thymocyte Globulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 38,
      "start_date": "2002-09",
      "completion_date": "2021-09-07",
      "has_results": false,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-07-23T22:07:07.976Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01019876"
    },
    {
      "nct_id": "NCT03315078",
      "title": "Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "X-Linked Combined Immunodeficiency Diseases"
      ],
      "interventions": [
        {
          "name": "CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Palifermin",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "2 Years to 40 Years"
      },
      "enrollment_count": 13,
      "start_date": "2012-04",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2019-12-04",
      "last_synced_at": "2026-07-23T22:07:07.976Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03315078"
    },
    {
      "nct_id": "NCT05545319",
      "title": "A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)",
        "Coronavirus Disease 2019 (COVID-19)",
        "Immunocompromised",
        "Hospitalization",
        "Child, Hospitalized"
      ],
      "interventions": [
        {
          "name": "Nirmatrelvir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Placebo for nirmatrelvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-12-13",
      "completion_date": "2024-01-06",
      "has_results": false,
      "last_update_posted_date": "2023-03-01",
      "last_synced_at": "2026-07-23T22:07:07.976Z",
      "location_count": 2,
      "location_summary": "Cooperstown, New York • New York, New York",
      "locations": [
        {
          "city": "Cooperstown",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05545319"
    },
    {
      "nct_id": "NCT01821781",
      "title": "Immune Disorder HSCT Protocol",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune Deficiency Disorders",
        "Severe Combined Immunodeficiency",
        "Chronic Granulomatous Disease",
        "X-linked Agammaglobulinemia",
        "Wiskott-Aldrich Syndrome",
        "Hyper-IgM",
        "DiGeorge Syndrome",
        "Chediak-Higashi Syndrome",
        "Common Variable Immune Deficiency",
        "Immune Dysregulatory Disorders",
        "Hemophagocytic Lymphohistiocytosis",
        "IPEX",
        "Autoimmune Lymphoproliferative Syndrome",
        "X-linked Lymphoproliferative Syndrome"
      ],
      "interventions": [
        {
          "name": "Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 20,
      "start_date": "2013-04-29",
      "completion_date": "2026-04",
      "has_results": false,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-07-23T22:07:07.976Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01821781"
    },
    {
      "nct_id": "NCT00794508",
      "title": "MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "ADA gene transfer",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Donald B. Kohn, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Month to 18 Years"
      },
      "enrollment_count": 10,
      "start_date": "2008-11",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2021-04-23",
      "last_synced_at": "2026-07-23T22:07:07.976Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00794508"
    },
    {
      "nct_id": "NCT04996797",
      "title": "A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Tulisokibart",
          "type": "DRUG"
        },
        {
          "name": "Companion Diagnostic (CDx) Testing",
          "type": "DEVICE"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2021-07-14",
      "completion_date": "2025-07-14",
      "has_results": true,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-07-23T22:07:07.976Z",
      "location_count": 29,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Sun City, Arizona + 24 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04996797"
    },
    {
      "nct_id": "NCT00055172",
      "title": "Genetic Basis of Immunodeficiency",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Severe Combined Immunodeficiency"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "6 Months to 99 Years"
      },
      "enrollment_count": 100,
      "start_date": "2004-04-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-07-23T22:07:07.976Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00055172"
    },
    {
      "nct_id": "NCT02177760",
      "title": "Sirolimus Prophylaxis for aGVHD in TME SCID",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency",
        "Transplacental Maternal Engraftment",
        "Stem Cell Transplant"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "1 Year",
        "sex": "ALL",
        "summary": "1 Day to 1 Year"
      },
      "enrollment_count": 0,
      "start_date": "2014-07",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2015-12-03",
      "last_synced_at": "2026-07-23T22:07:07.976Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02177760"
    },
    {
      "nct_id": "NCT01129544",
      "title": "Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Gene transfer",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "David Williams",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 8,
      "start_date": "2010-04",
      "completion_date": "2023-03",
      "has_results": true,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-07-23T22:07:07.976Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01129544"
    }
  ]
}